Stockscreener 앱 받기
21.93
1.31%
-0.29
시장 영업 전:
21.88
-0.05
-0.23%
전일 마감가:
$22.22
열려 있는:
$22.12
하루 거래량:
1.44M
Relative Volume:
0.81
시가총액:
$3.48B
수익:
$1.27M
순이익/손실:
$-508.02M
주가수익비율:
-7.6127
EPS:
-2.8807
순현금흐름:
$-419.23M
1주 성능:
+5.48%
1개월 성능:
+17.78%
6개월 성능:
+28.85%
1년 성능:
+50.00%
1일 변동 폭
$21.68
$22.47
1주일 범위
$20.16
$22.47
52주 변동 폭
$12.58
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
21.93 | 3.53B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
(DNLI) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Denali Therapeutics (DNLI) Rallies Over 3% as Stock Tests Key Resistance LevelsStock Analysis - newsline.com
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment - BioCentury
Denali Therapeutics stock (US24823R1077): Alzheimer’s data and Roche deal keep Wall Street watchin - AD HOC NEWS
Denali stock dips as Biogen-partnered Parkinson's disease study fails - MSN
Denali Therapeutics (DNLI) grants RSUs and stock options to director - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and options in new award - Stock Titan
Denali Therapeutics (DNLI) director receives RSU and stock option awards - Stock Titan
Director at Denali Therapeutics (NASDAQ: DNLI) receives RSUs and options - Stock Titan
Denali Therapeutics (DNLI) director receives new RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and stock options in new equity awards - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) details Baker RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay - Stock Titan
Responsive Playbooks and the DNLI Inflection - Stock Traders Daily
DNLI PE Ratio & Valuation, Is DNLI Overvalued - Intellectia AI
DNLI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos - Insider Monkey
Does Denali Therapeutics (DNLI) Parkinson’s Setback Reveal a Deeper Shift in Its Neuroscience Strategy? - simplywall.st
DNLI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline - Sahm
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - AOL.com
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data - Seeking Alpha
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says - Moomoo
DNLI Maintained by Morgan Stanley -- Price Target Lowered to $35 - GuruFocus
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss - Manufacturing Chemist
Biogen, Denali to drop Parkinson’s therapy after mid-stage trial setback - MSN
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Understanding the Setup: (DNLI) and Scalable Risk - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Intuitive Surgical (ISRG) - The Globe and Mail
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Is Early AVLAYAH Demand Reshaping The Investment Case For Denali Therapeutics’ Rare-Disease Platform (DNLI)? - Sahm
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating - Moomoo
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating - Moomoo
Denali Therapeutics stock falls after Parkinson’s drug fails trial By Investing.com - Investing.com South Africa
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):